Please login to the form below

Not currently logged in
Email:
Password:

Stem Cell Therapeutics

This page shows the latest Stem Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Bayer helps bankroll new stem cell company BlueRock

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies. There is a new player on the stem cell therapy stage, thanks to $225m in start-up funding from Bayer ... BlueRock's founding and scientific investigation team

Latest news

  • Orphan status for Stem Cell's leukaemia drug Orphan status for Stem Cell's leukaemia drug

    Tigecycline wins FDA rare disease designation. US regulators have granted orphan drug status to tigecycline, a cancer drug in development by Stem Cell Therapeutics. ... Tigecycline is being investigated by Stem Cell Therapeutics for its use in the

  • UK regenerative medicine projects get £8.5m boost

    Novel stem cell manufacturing technologies. • Cell labelling and tracking technologies for quality control and monitoring in the body. • ... Regenerative medicine is an interdisciplinary approach that spans tissue engineering, developmental and stem

  • Survival strategy

    Licenser/Partner. Product/Technology. Development status. Headline ($m). Mesoblast/Cephalon. Stem cell therapeutics in CHF. ... Immunotherapy company acquisition.  . 428. Theramex/Teva. Branded product company acquisition.  . 368. Evotec/MedImmune.

  • Diabetes favoured

    and Oncomed's $428m strategic alliance with Bayer Schering Pharma (BSP) to discover, develop and commercialise novel anti-cancer stem cell therapeutics. ... Anti-cancer stem cell therapy platform. Discovery. 428. Ascenta Therapeutics/sanofi-aventis.

  • Indian stem cell companies seek UK links

    Leading Indian stem cell companies are in the UK this week to seek ways to build links with the UK stem cell sector. ... Without UKTI's help, we would have had to spend a huge amount of time and expense trying to obtain all the required information on

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation.  Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast   . ... Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. †Hutchison MediPharma / Eli Lilly.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics